File Download
Supplementary
-
Citations:
- Appears in Collections:
postgraduate thesis: Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC)
Title | Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC) |
---|---|
Authors | |
Issue Date | 2011 |
Publisher | The University of Hong Kong (Pokfulam, Hong Kong) |
Citation | Choi, H. [蔡可盈]. (2011). Review of clinical benefits and cost effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first line treatment for patients with advanced non-small cell lung cancer (NSCLC). (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4693532 |
Degree | Master of Public Health |
Subject | Lungs - Cancer - Treatment. Epidermal growth factor - Receptors. Protein kinases - Inhibitors. |
Dept/Program | Public Health |
Persistent Identifier | http://hdl.handle.net/10722/145717 |
HKU Library Item ID | b4693532 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Ho-ying. | - |
dc.contributor.author | 蔡可盈. | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | Choi, H. [蔡可盈]. (2011). Review of clinical benefits and cost effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first line treatment for patients with advanced non-small cell lung cancer (NSCLC). (Thesis). University of Hong Kong, Pokfulam, Hong Kong SAR. Retrieved from http://dx.doi.org/10.5353/th_b4693532 | - |
dc.identifier.uri | http://hdl.handle.net/10722/145717 | - |
dc.language | eng | - |
dc.publisher | The University of Hong Kong (Pokfulam, Hong Kong) | - |
dc.relation.ispartof | HKU Theses Online (HKUTO) | - |
dc.rights | The author retains all proprietary rights, (such as patent rights) and the right to use in future works. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.source.uri | http://hub.hku.hk/bib/B46935320 | - |
dc.subject.lcsh | Lungs - Cancer - Treatment. | - |
dc.subject.lcsh | Epidermal growth factor - Receptors. | - |
dc.subject.lcsh | Protein kinases - Inhibitors. | - |
dc.title | Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC) | - |
dc.type | PG_Thesis | - |
dc.identifier.hkul | b4693532 | - |
dc.description.thesisname | Master of Public Health | - |
dc.description.thesislevel | Master | - |
dc.description.thesisdiscipline | Public Health | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.5353/th_b4693532 | - |
dc.date.hkucongregation | 2011 | - |
dc.identifier.mmsid | 991032516539703414 | - |